Meet-the-Expert Sessions

15 AUGUST 2025

Time
1500 – 1545

Venue
Singapore EXPO, Meeting Room Level 2, Peridot (201 – 203)

Introduction
In this interactive session, Prof Stephan Ehrmann will discuss optimising aerosol therapy in patients requiring respiratory support through modalities such as High Flow Nasal Cannula (HFNC), Non-Invasive Ventilation (NIV) and Invasive Mechanical Ventilation (IMV). He will also discuss the latest international consensus statement regarding aerosol delivery to critically ill patients across respiratory modalities and share his group’s latest research in inhaled therapeutics in this area.

Objectives

  • Discuss ways to optimise aerosol drug delivery across respiratory modalities
  • Discuss the benefits of in-line aerosol therapy across respiratory modalities
  • Present latest research in inhaled therapeutics

Faculty

Prof Stephan Ehrmann, Md, PhD

  • Professor of critical care medicine.
  • Intensive Care Unit of Tours University Hospital and Medical School, Tours University, Tours,
    France.
  • Pharmacology of inhaled pharmaceuticals, Research Centre for Respiratory Disease. UMR 1100 – Institut National de la Santé et de la Recherche biomédicale (INSERM), Tours, France.

Prof Ehrmann was trained as a critical care physician in Tours, France, and performed several parts of his training abroad: University of Heidelberg, Germany; Hospital Sant Pau Intensive Care Unit, Barcelona, Spain. He completed a PhD thesis in a laboratory focusing on respiratory and cell mechanics at the Paris-Est University, Paris, France. He focused his research on aerosol delivery to critically ill patients, performing large-scale observational studies and surveys on current practice, pharmacokinetic studies in animals and patients. Specifically, he developed in vitro, in vivo, and clinical research on aerosol delivery during nasal high flow therapy and coordinated one of the largest multicentre trials on prophylactic inhaled antibiotic therapy in intubated patients. He also coordinated international consensus work on aerosol therapy in critically ill patients.

Prof Ehrmann ran several large-scale clinical trials in the field of respiratory critical care, evaluating fasting prior to extubation, awake prone positioning among non-intubated patients, developing innovative devices for communication with intubated patients, and performing research in the fields of acute kidney injury and hemodynamic management of critically ill patients. Prof Ehrmann currently authored over 200 referenced scientific publications, gave over 100 invited national and international conferences, and his H-index is 50. He served as President of the French college of critical care scholars, chair of the epidemiology and research commission, and member of the scientific commission of the French Intensive Care Society. He completed two terms as a board member of the International Society for Aerosols in Medicine and chaired its networking group on new devices and emerging therapies. He also acted as a full-time advisor to the general directorate of healthcare
provision of the French Ministry of Health during the two pandemic years.

Currently, Prof Ehrmann is head of the Intensive Care Unit of Tours University Hospital, as well as President of the delegation for clinical research and innovation of the Centre Val de Loire region in France, Head of the technological innovation section of the clinical innovation center of Tours University Hospital, and co-coordinator of the International Clinical Research Network Crics-triggersep.

Session Schedule

1500 – 1540 | Presentation

1540 – 1545 | Closing Remarks

16 AUGUST 2025

Time

1515 – 1600

Venue

Singapore EXPO, Meeting Room, Level 2, Peridot (201 – 203)

Faculty

Prof Charles Feldman

Prof Charles Feldman is a Professor of Pulmonology and Chief Physician at Charlotte Maxeke Johannesburg Academic Hospital and Faculty of Health Sciences, University of the Witwatersrand. He obtained his undergraduate degree from the University of the

Witwatersrand in 1975 and his PhD (1991) and DSc (2009), both for theses on community-acquired pneumonia. He was registered as a sub-specialist in Pulmonology in 1993 and elected to the Fellowship of the Royal College of Physicians (FRCP) in 1997. In 1988/89, he was a Research Fellow and Honorary Senior Visiting Colleague in the Department of Thoracic Medicine, National Heart and Lung Institute, and Royal Brompton Hospital, London, United Kingdom. Prof Feldman is a member of a number of National and International Societies. He has been very active on the American Thoracic Society, serving on a number of Committees in Microbiology, Tuberculosis and Pulmonary Infection Assembly. He has been the South African Governor and Regent for the American College of Chest Physicians, and the National Delegate for South Africa to the European Thoracic Society. In 2014, he was elected as a Foundation Fellow of the European Respiratory Society in recognition of excellence in scientific and/or educational contributions to Respiratory Medicine over a number of years. He has been President of the South African Thoracic Society on two previous occasions. Prof Feldman is on the Executive Committee of FIDSSA in his role as Editor in Chief of the Southern African Journal of Infectious Diseases, a position he has held for a number of years. Prof Feldman’s research interest is in the field of community-acquired pneumonia, and in particular, pneumococcal pneumonia. In addition to being part of large international clinical collaborations, he also participates in basic research studies. He has more than 300 publications overall and is an NRF A-rated scientist.

Chairperson/Moderator

Dr Jim Teo

Session Schedule

1515 – 1520 | Introduction | Dr Jim Teo

1520 – 1525 | Burden of MDR gram-negative bacteria in ICU setting and risk factors associated with MDR gram-negative infections | Prof Charles Feldman
Possible coverage:

  • Epidemiology, Impact on Mortality, Length of Stay, Resistance variants seen in the ICU setting

1525 – 1535 | Diagnosis of MDRO infections in ICU using Rapid Diagnostic Tools to guide early antibiotic selection | Prof Charles Feldman
Possible coverage:

  • Blood culture PCR, Multiplex PCR Panel, Xpert-Carba R Assays, Carba-5 Lateral Flow Assays
  • Studies showing the impact of early appropriate therapy

1535 – 1540 | RWE on Zavicefta use in critically ill CP-CRE patients | Prof Charles Feldman

1540 – 1550 | Case study on incorporating RDTs in Critically-ill ICU Patient treatment journey with Zavicefta | Prof Charles Feldman

1550 – 1600 | Q&A

ORGANISED BY

MANAGED BY

Kenes MP Asia Pte Ltd
Asia Pacific Intensive Care Symposium (APICS) 2025
20 Kallang Avenue, PICO Creative Centre, Level 2
Singapore 339411

CONTACT US

General Enquiries:

Registration Enquiries:

Abstract Enquiries: